Bruce C. Cozadd - Oct 3, 2022 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Chairman & CEO, Director
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Stock symbol
JAZZ
Transactions as of
Oct 3, 2022
Transactions value $
-$2,377,334
Form type
4
Date filed
10/5/2022, 06:43 PM
Previous filing
Sep 8, 2022
Next filing
Nov 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Options Exercise $3.72M +62.9K +17.65% $59.13 419K Oct 3, 2022 Direct
transaction JAZZ Ordinary Shares Sale -$1.85M -13.8K -3.29% $134.02 405K Oct 3, 2022 Direct F1, F2
transaction JAZZ Ordinary Shares Sale -$3.2M -23.6K -5.83% $135.18 382K Oct 3, 2022 Direct F1, F3
transaction JAZZ Ordinary Shares Sale -$1.05M -7.75K -2.03% $135.80 374K Oct 3, 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -62.9K -100% $0.00* 0 Oct 3, 2022 Ordinary Shares 62.9K $59.13 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F2 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.56 to $134.54. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.57 to $135.56. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.57 to $136.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F6 This non-qualified stock option is part of an option granted on March 5, 2013. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of March 5, 2017.